Weuphoria (PCV13-TT) / Walvax - LARVOL DELTA

Antibody persistence in Chinese toddlers at 1 year and 2 years after two different 4-dose schedules of a novel 13-valent pneumococcal conjugate vaccine (PCV13-TT). (PubMed, Vaccine) - "After complete dosing schedule of PCV13-TT starting from either 2 months or 3 months, the antibody level declined through 1 year and 2 years post booster dose, while still remained at relatively high levels at the two timepoints as compared to those observed at 1 month post booster dose for the majority of serotypes."

Journal • Infectious Disease • Pneumococcal Infections

A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13 (clinicaltrials.gov) - P3 | N=630 | Active, not recruiting | Sponsor: Walvax Biotechnology Co., Ltd. | Enrolling by invitation ➔ Active, not recruiting | Trial completion date: Sep 2025 ➔ Feb 2026 | Trial primary completion date: Dec 2024 ➔ Mar 2025

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

Analysis of Adverse Events Post-13-Valent Pneumococcal Vaccination among Children in Hangzhou, China. (PubMed, Vaccines (Basel)) - "No statistically significant difference was observed between PCV13-TT and PCV-CRM197...Four serious AEFI cases were coincidental events, while three others were considered vaccine-related cases (including one case each of allergic reaction, febrile seizure, and thrombocytopenia). The safety and tolerability of PCV13 are good, and attention should be paid to severe AEFIs, as well as long-term safety disparities between different types of PCV13."

Adverse events • Journal • Pneumococcal vaccines • Allergy • CNS Disorders • Epilepsy • Hematological Disorders • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases • Thrombocytopenia • ROR1

ANTIBODY PERSISTENCE IN CHINESE INFANTS AT 1 YEAR AND 2 YEARS AFTER TWO DIFFERENT 4-DOSE SCHEDULES OF A NOVEL 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13-TT) (ISPPD 2024) - "Two different priming schedules of PCV13-TT incur similar antibody persistence with respect to the common serotypes of PCV7, and PCV13-TT shows higher potential in providing protection against the 6 additional serotypes."

Infectious Disease • Pneumococcal Infections

A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13 (clinicaltrials.gov) - P3 | N=600 | Enrolling by invitation | Sponsor: Walvax Biotechnology Co., Ltd. | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Infectious Disease • Pneumococcal Infections

A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13 (clinicaltrials.gov) - P3 | N=600 | Not yet recruiting | Sponsor: Walvax Biotechnology Co., Ltd.

New P3 trial • Infectious Disease • Pneumococcal Infections